Cancer Discovery 2019-Aug
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech.
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
De link wordt op het klembord opgeslagen
Sleutelwoorden
Abstract
Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of TGFβ, a cytokine involved in thwarting the effectiveness of cancer immunotherapies.
